Transgenic Overexpression of Protein-tyrosine Phosphatase 1B in Muscle Causes Insulin Resistance, but Overexpression with Leukocyte Antigen-related Phosphatase Does Not Additively Impair Insulin Action

Janice M Zabolotny,Fawaz G Haj,Young-Bum Kim,Hyo-Jeong Kim,Gerald I Shulman,Jason K Kim,Benjamin G Neel,Barbara B Kahn

doi:10.1074/jbc.m310688200

Abstract

Previous studies implicate protein-tyrosine phosphatase 1B (PTP1B) and leukocyte antigen-related phosphatase (LAR) as negative regulators of insulin signaling. The expression and/or activity of PTP1B and LAR are increased in muscle of insulin-resistant rodents and humans. Overexpression of LAR selectively in muscle of transgenic mice causes whole body insulin resistance. To determine whether overexpression of PTP1B also causes insulin resistance, we generated transgenic mice overexpressing human PTP1B selectively in muscle at levels similar to those observed in insulin-resistant humans. Insulin-stimulated insulin receptor (IR) tyrosyl phosphorylation and phosphatidylinositol 3'-kinase activity were impaired by 35% and 40-60% in muscle of PTP1B-overexpressing mice compared with controls. Insulin stimulation of protein kinase C (PKC)lambda/zeta activity, which is required for glucose transport, was impaired in muscle of PTP1B-overexpressing mice compared with controls, showing that PTP1B overexpression impairs activation of these PKC isoforms. Furthermore, hyperinsulinemic-euglycemic clamp studies revealed that whole body glucose disposal and muscle glucose uptake were decreased by 40-50% in PTP1B-overexpressing mice. Overexpression of PTP1B or LAR alone in muscle caused similar impairments in insulin action; however, compound overexpression achieved by crossing PTP1B- and LAR-overexpressing mice was not additive. Antibodies against specific IR phosphotyrosines indicated overlapping sites of action of PTP1B and LAR. Thus, overexpression of PTP1B in vivo impairs insulin sensitivity, suggesting that overexpression of PTP1B in muscle of obese humans and rodents may contribute to their insulin resistance. Lack of additive impairment of insulin signaling by PTP1B and LAR suggests that these PTPs have overlapping actions in causing insulin resistance in vivo.

Highlights

To verify that in muscle creatine kinase (MCK)-hLAR/ protein-tyrosine phosphatase 1B (PTP1B) mice, overexpression of PTP1B in muscle was similar to MCK-PTP1B mice and overexpression of leukocyte antigenrelated (LAR) in muscle was similar to MCK-hLAR mice, we measured human and murine PTP1B protein and total LAR protein in muscle of WT, MCKhLAR, MCK-hPTP1B, and MCK-hLAR/PTP1B mice
LAR expression was similar in muscles of WT and muscle insulin receptor-deficient (MIRKO) mice (Fig. 2B), an animal model in which insulin signaling is absent in muscle, suggesting that insulin resistance in muscle does not alter LAR expression
Our data demonstrate that overexpression of PTP1B in muscle in vivo impairs insulin signaling in muscle and results in whole body insulin resistance

Summary

Introduction

The level of transgenic PTP1B overexpression observed in MCK-hPTP1B mice is similar to that observed in skeletal muscle of insulin-resistant humans and rodents [7,8,9]. The glucose infusion rate was decreased by 36% in MCK-hLAR/PTP1B mice (Fig. 3A), indicating that compound overexpression of LAR and PTP1B in skeletal muscle does not additively impair insulin action.

Results

Conclusion